A study using brain imaging and biomarker data identified three distinct patterns of cognitive decline in people with preclinical Alzheimer's disease.
Key Details
- 1Researchers analyzed 6-year data from the A4 and LEARN studies, involving people with preclinical Alzheimer's.
- 2Three cognitive trajectories were identified: stable, slow decline, and fast decline; 70% of participants remained stable.
- 3Higher baseline levels of phosphorylated tau (P-tau217) and brain scan tau markers, as well as smaller hippocampal volumes, predicted greater cognitive decline.
- 4Biomarker models could predict stable vs. declining status with about 70% accuracy.
- 5Findings suggest many clinical trial participants do not decline, complicating drug effect measurement.
Why It Matters
The study advances understanding of heterogeneity in Alzheimer's progression and highlights the potential for imaging biomarkers (e.g., PET, MRI) to inform prognosis and participant selection in clinical trials. Improved prediction via imaging and AI could optimize trial design and enable more personalized care in neurodegenerative disease.
Source
EurekAlert
Related News
•EurekAlert
USC Receives $3M Gift for Alzheimer's Research Involving Imaging and AI
A $3 million donation to USC will accelerate Alzheimer's research, including imaging modality development and AI-based molecular analysis.
•EurekAlert
AI Pathology Analysis Predicts Immunotherapy Response in Rare Tumors
AI-based analysis of tumor pathology slides can predict immunotherapy outcomes in rare cancers, according to a recent MD Anderson study.
•EurekAlert
Review Highlights AI's Impact on Breast Cancer Imaging and Recurrence Prediction
A major review details how AI enhances early detection and recurrence prediction in breast cancer imaging.